BellBrook Labs Awarded NIH Grant to Validate New Target for Liver Fibrosis Using Transcreener GTPase Assay Platform
Wednesday, 09 November 2016
BellBrook Labs was awarded a Phase I Small Business Innovative Research (SBIR) grant of $353,000 from the National Institute on Alcohol Abuse and Alcoholism for pharmacological validation of GIV, a nonreceptor guanine nucleotide exchange factor (GEF), as a therapeutic target for liver fibrosis. BellBrook will use proprietary high throughput GTPase assay methods to identify small
No Comments
ICBS Conference 2016
Thursday, 06 October 2016
Location: Madison, WI Date: October 24-26 BellBrook Labs’ team of scientists will be presenting the following posters at the International Chemical Biology Society. A Homogenous, Universal Methyltransferase Assay Based on a Microbial Riboswitch Leveraging Aptamers for Detection of Growth Factors in an HTS Compatible Format: An AptaFluor™ VEGF Assay Measuring Drug Residence Times
Posters and Presentations from DOT 2016
Friday, 30 September 2016
Did you miss the DOT 2016 meeting in Boston or would like a recap? View the posters and presentations from BellBrook’s scientists below. Posters: Aptamer Based Homogenous Single-Reagent HTS Assay Platform for Human Growth Factors Aniket, Elizabeth Vu, Meera Kumar, Tom Zielinski, Justin Brink, and Robert G. Lowery Determination of Drug Residence Time in a
BellBrook Labs Receives NIH Funding to Commercialize Methyltransferase Assays for Epigenetic Drug Discovery
Tuesday, 30 August 2016
BellBrook Labs has been awarded an $860,000 Phase II SBIR grant from the National Institutes of General Medical Sciences to develop an innovative methyltransferase assay for epigenetic drug discovery. The company’s scientists engineered a fluorescent light switch into a bacterial metabolite sensor to leap-frog the limitations of conventional reagents. Madison, WI – August 31, 2016
- Published in Company, Epigenetics, News
Discovery on Target Conference 2016
Wednesday, 17 August 2016
Discovery on Target 2016 September 19-22 Westin Boston Waterfront Boston, MA Exhibition Visit Booth #24 to: Discuss BellBrook’s current HTS assays. Share your thoughts on the future of drug discovery. Learn about upcoming AptaFluor™ HTS assays! Presentations/Talks AptaFluor™ Methyltransferase Assay: A Homogenous, Universal HMT Assay Based on a Microbial Riboswitch Tuesday, September 20th – 3:15PM Poster
- Published in News
New Publication: TR-FRET Assay for UDP-Glycosyltransferases
Thursday, 26 May 2016
See our latest publication, “Development and Validation of a Universal High-Throughput UDP-Glycosyltransferase Assay with a Time-Resolved FRET Signal” in ASSAY and Drug Development Technologies BellBrook Labs scientist Tom Zielinski collaborated with investigators in Mel Reichman and Preston Donover of the Lankenau Institute for Medical Research to develop a robust assay method for screening and profiling
- Published in News
View our SLAS 2016 posters
Monday, 08 February 2016
View the posters our BellBrook Labs scientists presented at SLAS 2016 and learn how we are using Transcreener® HTS Assays to accelerate screening and lead optimization for kinases, ATPases, glycosyltransferases, GAP and GEF proteins, epigenetic “writers,” and other enzyme targets. View our posters: Determination of Drug Residence Times in a HTS format using Kinetic Analysis
- Published in News
Join us in San Diego for SLAS 2016
Monday, 18 January 2016
SLAS 2016 conference and exhibition (January 23–27) Visit with BellBrook Labs scientists and our collaborators at SLAS 2016 to learn how we are using Transcreener® HTS Assays to accelerate screening and lead optimization for kinases, ATPases, glycosyltransferases, GAP and GEF proteins, epigenetic “writers,” and other enzyme targets. Attend our tutorial in collaboration with BMG LABTECH:
- Published in News
Learn how to use our Transcreener® GDP Assay for screening GAPs and GEFs in our recorded webinar
Friday, 27 November 2015
Our recorded webinar for Screening GAPs and GEFs with the Transcreener® GDP Assay is now available for viewing anytime In Interrogating GTPase Effector Proteins: Screening GAPs and GEFs with the Transcreener® GDP Assay, a recorded webinar presented by BellBrook Labs scientist Meera Kumar, you can learn about our HTS-compatible Transcreener® GDP Assay methods for detection
- Published in News
New Case Study: Discovery of GALNT3 Inhibitors Using a Universal Glycosyltransferase Assay and Orthogonal Pooled Screening
Friday, 27 November 2015
Glycosyltransferase (GT) enzymes participate in diverse metabolic and regulatory roles by catalyzing the transfer of sugars to protein, lipid and carbohydrate acceptors as well as to other molecules. Within the GT family, there are over 20 distinct polypeptide N-acetylgalactosaminyltransferases (GALNTs) that catalyze the initial step of O-glycosylation. GALNT3 overexpression and dysregulation has been directly linked